Sign In
Buy ROG
$148.00
-6.22 (-4.03%)
At Close: Jun 03, 2026
Rogers Corporation (ROG) Q4 2022 Earnings Call Transcript
10:47pm, Tuesday, 28'th Feb 2023
Rogers Corporation (NYSE:ROG ) Q4 2022 Results Conference Call February 28, 2023 5:00 PM ET Company Participants Steve Haymore - Director, Investor Relations Colin Gouveia - President and CEO Ram Maya
Starboard nominates directors to the board at Rogers. Here's how the firm could boost margins
08:33am, Saturday, 11'th Feb 2023
In December, Starboard nominated four directors for election to the board at materials company Rogers.
Rogers Corporation: I Bought, Did You?
12:59pm, Friday, 20'th Jan 2023
My last article on Rogers Corporation was about a look at an undervalued business after a failed M&A. The market pushed the company down to unrealistic levels. My stance was "BUY" - and the result, as
5 Best and Worst Performing Mid-Cap Stocks in Q4 2022
10:53pm, Thursday, 19'th Jan 2023
Mid-cap stocks are proving to be an attractive investment option over the past few years.
Rogers to Participate in CJS Securities Investor Conference
06:45am, Wednesday, 11'th Jan 2023
CHANDLER, Ariz.--( BUSINESS WIRE )--Rogers Corporation (NYSE:ROG) announced that senior management will participate in the CJS Securities 23rd Annual New Ideas for the New Year Conference, today Wedne
What to know about the Alzheimer’s drug data coming out this week
07:15pm, Wednesday, 30'th Nov 2022 MarketWatch
Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week.
Rogers To Hold Investor Conference Call On December 8, 2022
05:00pm, Monday, 28'th Nov 2022
CHANDLER, Ariz.--( BUSINESS WIRE )--Rogers Corporation (NYSE:ROG) (“Rogers”) today announced that it will hold a conference call for analysts and investors on December 8, 2022 at 4:30 pm ET. The C
Is FlexShares International Quality Dividend ETF (IQDF) a Strong ETF Right Now?
11:20am, Friday, 25'th Nov 2022 Zacks Investment Research
Smart Beta ETF report for IQDF
Should You Invest in the Invesco S&P SmallCap Information Technology ETF (PSCT)?
11:20am, Wednesday, 16'th Nov 2022 Zacks Investment Research
Sector ETF report for PSCT
Roche gets FDA Emergency Use Authorization for Monkeypox virus test
06:58am, Wednesday, 16'th Nov 2022 MarketWatch
Cobas MPXV is a real-time PCR test which detects the presence of monkeypox virus DNA from lesion swabs, the Swiss medical company said.
Roche receives U.S. FDA Emergency Use Authorization for its high-throughput test to detect monkeypox virus
06:00am, Wednesday, 16'th Nov 2022 GlobeNewswire Inc.
Basel, 16 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for cobas® MPXV for use on the
One Alzheimer's drug has failed, but investors are still betting on Biogen and Lilly treatments
12:14pm, Tuesday, 15'th Nov 2022 MarketWatch
Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s disease
06:00am, Monday, 14'th Nov 2022 GlobeNewswire Inc.
Basel, 14 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the GRADUATE I and II studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Al
STRONG-HF study results demonstrate clear benefits for acute heart failure patients
06:00am, Wednesday, 09'th Nov 2022 GlobeNewswire Inc.
Basel, 9 November 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced publication of the Safety, Tolerability and Efficacy of Rapid Optimization of Heart Failure (STRONG-HF) study in patients ho
Rogers: Why The Company Is Worth More Than $100 After Third-Quarter Results
04:51am, Wednesday, 09'th Nov 2022
The Rogers deal with DuPont fell through last week, leading to a massive share price drop of close to 50% to the company's previous valuation. Some are saying it's a massive overreaction. Others are s
